ホーム › 骨髄増殖性腫瘍 › マサチューセッツ州 › Boston
Boston、MAにおける骨髄増殖性腫瘍の臨床試験
Bostonとその周辺地域（約30マイル以内）の拠点で、骨髄増殖性腫瘍に関する14件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
被験者募集中第2相
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
被験者募集中第2相
- Dana-Farber Cancer Institute, Boston
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
被験者募集中第1/2相
- Dana-Farber Cancer Institute, Boston
Project: Every Child for Younger Patients With Cancer
被験者募集中観察研究
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
被験者募集中第1相健康なボランティア歓迎
- Brigham and Women's Hospital, Boston
Ropeginterferon for High Risk JAK2 Clonal Hematopoiesis
被験者募集中第1相
- Mass General Brigham, Boston
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
被験者募集中第1相
- Massachusetts General Hospital, Boston
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
被験者募集中第1相
- Boston Children's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
被験者募集中第1相
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
被験者募集中第1相
- Dana Farber Cancer Institute, Boston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
被験者募集中第2相
- Dana-Farber Cancer Institute, Boston
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
被験者募集中第2相健康なボランティア歓迎
- DFCI/BWH Brigham and Women's Hospital, Boston
I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients
被験者募集中
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Massachusetts General Hospital Cancer Center, Boston
他の都市における骨髄増殖性腫瘍の試験
- Houston, TX16件の研究
- New York City, NY15件の研究
- Milwaukee, WI10件の研究
- Miami, FL10件の研究
- Durham, NC9件の研究
- Baldwin Park, CA9件の研究
- Seattle, WA9件の研究
- Chicago, IL9件の研究
- Portland, OR8件の研究
- Cleveland, OH8件の研究
- Atlanta, GA8件の研究
- Philadelphia, PA8件の研究
Bostonにおける他の研究
- 乳がん112件の研究
- 非小細胞肺癌90件の研究
- がん（全種類）85件の研究
- 転移性癌63件の研究
- 大腸癌63件の研究
- 肺がん62件の研究
- 卵巣がん61件の研究
- 前立腺がん59件の研究
- うつ病52件の研究
- 子宮内膜がん50件の研究
- 心不全44件の研究
- 急性骨髄性白血病44件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。